Welcome to our dedicated page for Omada Health SEC filings (Ticker: OMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omada Health, Inc. (Nasdaq: OMDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a virtual-first, between-visit healthcare provider focused on cardiometabolic and musculoskeletal conditions, Omada uses these filings to report on its financial condition, operations, and material events related to its digital chronic care platform.
Investors can review current reports on Form 8-K, which Omada uses to furnish press releases announcing quarterly results and other significant developments. For example, recent 8-K filings reference earnings press releases for periods in which the company reported revenue, member growth, and updates on its GLP-1-related offerings and AI capabilities. These current reports help readers connect headline financial and operational metrics to the underlying SEC record.
In addition to 8-Ks, Omada’s periodic reports on Form 10-Q and Form 10-K (accessible through the SEC and linked from this page when available) typically contain more detailed information on revenue composition, cost structure, research and development spending, and risks associated with its virtual care and GLP-1 programs. These filings are particularly relevant for understanding how Omada’s cardiometabolic and musculoskeletal programs, GLP-1 Care Tracks, and prescribing and medication management capabilities are reflected in its financial statements and risk disclosures.
Stock Titan enhances this information with AI-powered summaries that explain key points from lengthy filings, helping readers quickly identify sections related to Omada’s chronic care model, GLP-1 initiatives, and digital health operations. Users can also monitor updates to OMDA’s filings in near real time, including new 8-Ks, 10-Qs, 10-Ks, and other relevant forms, to follow how the company reports on its performance and material events over time.
OMDA Section 144 disclosure reports securities transactions related to option exercises and programmed sales. The filing lists 2,084 shares tied to an exercise of stock options on 06/26/2026 and multiple 10b5-1 sales: 2,083 shares on 06/24/2026, 2,083 shares on 06/22/2026, and 6,894 shares on 06/12/2026. The record shows 59,448,507 (numeric string as provided) in a securities field dated 06/26/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed sales of 14,158 shares of common stock tied to an exercise of stock options effective 06/26/2026. The filing also lists recent 10b5-1 sales by Sean Duffy totaling reported trades of 300, 2,800, and 14,960 shares on 06/25/2026, 06/24/2026, and 06/16/2026.
OMDA reported insider sales in a Form 144 notice by Sean Duffy. The filing lists a 300-share transaction tied to an exercise of stock options on 06/25/2026 and two prior 10b5-1 sales: 2,800 shares on 06/24/2026 for $53,238.92 and 14,960 shares on 06/16/2026 for $259,711.58.
The transactions are presented as sales under a 10b5-1 plan and an option exercise; cash-flow treatment for the option exercise is listed as Cash.
OMDA reported a Form 144 disclosing insider dispositions of Common Stock. The filing lists a planned sale tied to an exercise of stock options for 300 shares on 06/25/2026 (cash exercise). The filing also records recent 10b5-1 sales by Steven L. Cook: 2,600 shares on 06/24/2026, 17,950 shares on 06/22/2026, and 6,800 shares on 06/15/2026
Omada Health, Inc. President Shao Wei-Li reported an amended open-market sale of 4,037 shares of Common Stock. The shares were sold on June 12, 2026 at a weighted average price of $17.2407 per share, leaving 316,790 shares beneficially owned afterward.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. This Form 4/A corrects an earlier filing that had overstated the number of shares sold and the President’s resulting share ownership due to an administrative broker error.
Affiliate files to sell 2,800 shares of Common Stock. The filing lists 2,800 shares offered on 06/24/2026 via the exercise of stock options for cash. The excerpt also shows a 10b5-1 sale of 14,960 shares on 06/16/2026 for $259,711.58. Shares outstanding are shown as 59,448,507 as of 06/24/2026.
OMDA reported a proposed disposition of 2,083 shares of Common Stock via exercise of stock options on 06/24/2026. The filing lists $38,118.90 associated with the 2,083-share entry and shows 59,448,507 shares outstanding as of 06/24/2026 as context. The excerpt also lists prior 10b5-1 sales by Craig Gracey: 2,083 shares on 06/22/2026 for $37,494.00 and 6,894 shares on 06/12/2026 for $120,123.06.
OMDA reports proposed and completed sales of Common Stock. The filing lists an issuer sale of 2,600 shares tied to an exercise of stock options for cash on 06/24/2026. It also documents 10b5-1 sales by Steven L. Cook of 17,950 shares on 06/22/2026 for $325,394.01 and 6,800 shares on 06/15/2026 for $117,183.72.
The filing is administrative: it records the planned issuer sale tied to option exercise and the reported 10b5-1 transactions; cash‑flow recipients and broader timing mechanics are stated next to each line item.
Omada Health, Inc. Chief Financial Officer Steven L. Cook sold 17,950 shares of common stock in an open-market transaction at a weighted average price of $18.1278 per share. Following this sale, he directly holds 169,259 shares. The trade was made pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2026.
Omada Health, Inc. Chief Accounting Officer Craig Gracey reported an open-market sale of 2,083 shares of common stock at $18.0000 per share on June 22, 2026. After this transaction, Gracey directly holds 7,108 shares. The filing notes the trade was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026.